Vandetanib Doesn't Up Survival in Non-Small-Cell Lung Cancer

For patients with advanced NSCLC, no survival benefit; increased frequency of adverse events

THURSDAY, March 1 (HealthDay News) -- Vandetanib does not improve overall survival for patients who have received previous treatment for advanced non-small-cell lung cancer (NSCLC), according to a study published online Feb. 27 in the Journal of Clinical Oncology.

Jin Soo Lee, M.D., of the Sungkyunkwan University School of Medicine in Seoul, South Korea, and colleagues randomly assigned patients with advanced NSCLC, who had previously been treated with an epidermal growth factor receptor tyrosine kinase inhibitor and one or two chemotherapy regimens, in a 2:1 ratio to receive vandetanib 300 mg/day (617 patients) or placebo (307 patients) until either the disease progressed or unacceptable toxicity was reached.

The researchers found that there was no significant increase in overall survival in the vandetanib cohort compared with placebo (hazard ratio [HR], 0.95; P = 0.527), with median overall survival of 8.5 and 7.8 months for vandetanib and placebo patients, respectively. For progression-free survival (HR, 0.63) and objective response rate (2.6 versus 0.7 percent), statistically significant advantages favoring vandetanib were observed. The number and type of post-progression therapy was similar between the cohorts. Adverse events were consistent with previous NSCLC studies of vandetanib 300 mg, with common events (including diarrhea, rash, and hypertension) occurring more frequently in the vandetanib cohort versus the placebo group.

"The study did not demonstrate an overall survival benefit for vandetanib versus placebo," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including AstraZeneca, which funded the study and manufactures vandetanib.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles

Blunt Chest Trauma
Journal of Trauma Nursing, November/December 2014
Expires: 12/31/2016 CE:2 $21.95


The School Age Child with Congenital Heart Disease
MCN, The American Journal of Maternal/Child Nursing, January/February 2015
Expires: 2/28/2017 CE:2.5 $24.95


Understanding multiple myeloma
Nursing Made Incredibly Easy!, January/February 2015
Expires: 2/28/2017 CE:2 $21.95


More CE Articles

Subscribe to Recommended CE

Recommended Nursing Articles

Comprehensive Care: Looking Beyond the Presenting Problem
Journal of Christian Nursing, January/March 2015
Free access will expire on March 2, 2015.


Pain and Alzheimer dementia: A largely unrecognized problem
Nursing Made Incredibly Easy!, January/February 2015
Free access will expire on February 16, 2015.


Glycemic control in hospitalized patients
Nursing2015 Critical Care, January 2015
Free access will expire on February 16, 2015.


More Recommended Articles

Subscribe to Recommended Articles

Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events